ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $264,432 | -24.3% | 7,419 | -2.1% | 0.00% | -100.0% |
| Q2 2023 | $349,298 | +55.9% | 7,578 | +35.4% | 0.00% | – |
| Q1 2023 | $224,063 | -2.2% | 5,596 | +14.0% | 0.00% | – |
| Q4 2022 | $229,000 | +41.4% | 4,908 | +26.2% | 0.00% | – |
| Q3 2022 | $162,000 | -5.3% | 3,890 | +34.6% | 0.00% | – |
| Q2 2022 | $171,000 | -13.6% | 2,890 | +2.7% | 0.00% | – |
| Q1 2022 | $198,000 | -16.1% | 2,815 | -0.5% | 0.00% | – |
| Q4 2021 | $236,000 | +61.6% | 2,830 | +75.6% | 0.00% | – |
| Q3 2021 | $146,000 | +19.7% | 1,612 | +26.6% | 0.00% | – |
| Q2 2021 | $122,000 | -60.1% | 1,273 | -52.4% | 0.00% | -100.0% |
| Q1 2021 | $306,000 | +20.9% | 2,674 | +46.8% | 0.00% | 0.0% |
| Q4 2020 | $253,000 | +97.7% | 1,822 | +15.8% | 0.00% | – |
| Q3 2020 | $128,000 | +42.2% | 1,574 | +36.2% | 0.00% | – |
| Q2 2020 | $90,000 | +109.3% | 1,156 | +20.5% | 0.00% | – |
| Q1 2020 | $43,000 | – | 959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |